Enzene Biosciences launches Ranibizumab to treat neovascular AMD
Ranibizumab biosimilar is the company’s seventh biosimilar
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
ranibizumab
FDA approves Roche’s Susvimo for neovascular or “wet” age-related macular degeneration (nAMD)
Susvimo, previously called Port Delivery System with ranibizumab, is the first nAMD treatment in 15 years to provide an…
Intas launches RAZUMAB, the first biosimilar to Lucentis (ranibizumab)
Ranibizumab is indicated for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD), a common degenerative…